{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-083664","form_type":"8-K","ticker":"CVRX","cik":"0001235912","company_name":"CVRx, Inc.","filed_at":"2022-07-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.178352+00:00","generated_at":"2026-06-24T07:19:05.472570+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CVRx Q2 revenue $5.0M (+61% YoY); HF revenue up 90% in US; FY guidance raised","bullets":["Revenue $5.0M (+61% YoY), US HF revenue $3.8M (+90% YoY) driven by territory expansion.","Active US implanting centers reached 71 (+27% QoQ); sales territories grew to 20 from 8 a year ago.","Net loss narrowed to $11.1M ($0.54/shr) from $17.7M; cash $121.3M at quarter end.","FY2022 revenue guidance raised lower end to $20.5M (range $20.5-$23.0M); gross margin guidance 75-76%.","Received FDA approval for new tablet programmer and MR conditional labeling for Barostim."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-083664","json":"https://secwatch.observer/filing/0001104659-22-083664.json","markdown":"https://secwatch.observer/filing/0001104659-22-083664.md","text":"https://secwatch.observer/filing/0001104659-22-083664.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1235912/000110465922083664/0001104659-22-083664-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1235912/000110465922083664/tm2221895d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T07:19:05.472570+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}